Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution of the eczema; and (iii) chronic and chronically relapsing course. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Original languageEnglish
Pages (from-to)1117-1145
Number of pages29
JournalJournal of Dermatology
Volume43
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Practice Management
Atopic Dermatitis
Practice Guidelines
Eczema
Pruritus
Emollients
Evidence-Based Medicine
Tacrolimus
Ointments
Counseling
Japan
Adrenal Cortex Hormones
Guidelines
Psychology
Inflammation
Skin
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association (2016). Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. Journal of Dermatology, 43(10), 1117-1145. https://doi.org/10.1111/1346-8138.13392

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. / Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association.

In: Journal of Dermatology, Vol. 43, No. 10, 01.10.2016, p. 1117-1145.

Research output: Contribution to journalArticle

Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association 2016, 'Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016', Journal of Dermatology, vol. 43, no. 10, pp. 1117-1145. https://doi.org/10.1111/1346-8138.13392
Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. Journal of Dermatology. 2016 Oct 1;43(10):1117-1145. https://doi.org/10.1111/1346-8138.13392
Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association. / Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. In: Journal of Dermatology. 2016 ; Vol. 43, No. 10. pp. 1117-1145.
@article{7f9ad5483e1449c1832aefc2a8b42189,
title = "Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016",
abstract = "Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution of the eczema; and (iii) chronic and chronically relapsing course. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.",
author = "{Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association} and Hidehisa Saeki and Takeshi Nakahara and Akio Tanaka and Kenji Kabashima and Makoto Sugaya and Hiroyuki Murota and Tamotsu Ebihara and Yoko Kataoka and Michiko Aihara and Takafumi Etoh and Norito Katoh",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/1346-8138.13392",
language = "English",
volume = "43",
pages = "1117--1145",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

AU - Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association

AU - Saeki, Hidehisa

AU - Nakahara, Takeshi

AU - Tanaka, Akio

AU - Kabashima, Kenji

AU - Sugaya, Makoto

AU - Murota, Hiroyuki

AU - Ebihara, Tamotsu

AU - Kataoka, Yoko

AU - Aihara, Michiko

AU - Etoh, Takafumi

AU - Katoh, Norito

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution of the eczema; and (iii) chronic and chronically relapsing course. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

AB - Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The definitive diagnosis of AD requires the presence of all three features: (i) pruritus; (ii) typical morphology and distribution of the eczema; and (iii) chronic and chronically relapsing course. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84963858661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963858661&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.13392

DO - 10.1111/1346-8138.13392

M3 - Article

VL - 43

SP - 1117

EP - 1145

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 10

ER -